Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment....
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2007-06, Vol.13 (11), p.3207-3214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3214 |
|---|---|
| container_issue | 11 |
| container_start_page | 3207 |
| container_title | Clinical cancer research |
| container_volume | 13 |
| creator | DESMEDT, Christine PIETTE, Fanny BERGH, Jonas LIDEREAU, Rosette ELLIS, Paul HARRIS, Adrian L KLIJN, Jan G. M FOEKENS, John A CARDOSO, Fatima PICCART, Martine J BUYSE, Marc SOTIRIOU, Christos LOI, Sherene YIXIN WANG LALLEMAND, Frangoise HAIBE-KAINS, Benjamin VIALE, Giuseppe DELORENZI, Mauro YI ZHANG SAGHATCHIAN D'ASSIGNIES, Mahasti |
| description | Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results
and to compare the outcome with clinical risk assessment.
Experimental Design: Gene expression profiling of frozen samples from 198 N − systemically untreated patients was done at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic
risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were done with
the genomic risk and adjusted for the clinical risk, defined by Adjuvant! Online.
Results: The actual 5- and 10-year time to distant metastasis were 98% (88-100%) and 94% (83-98%), respectively, for the good profile
group and 76% (68-82%) and 73% (65-79%), respectively, for the poor profile group. The actual 5- and 10-year overall survival
were 98% (88-100%) and 87% (73-94%), respectively, for the good profile group and 84% (77-89%) and 72% (63-78%), respectively,
for the poor profile group. We observed a strong time dependence of this signature, leading to an adjusted hazard ratio of
13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for time to distant
metastasis and overall survival, respectively.
Conclusion: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene
expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases. |
| doi_str_mv | 10.1158/1078-0432.CCR-06-2765 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_569852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21044873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c605t-c7dd13f6813320b106e0d3c41de5aebb18e8e839f11a9d9dfe53bf1a12c44903</originalsourceid><addsrcrecordid>eNqFkc1u1DAQgCMEoqXwCCBfQOohxY7tODm2oSwrlaXqrrhajjPJGrLxYjtUPAzvitMEekQ-eDT-5kf-kuQ1wReE8OI9waJIMaPZRVXdpThPM5HzJ8kp4VykNMv50xj_ZU6SF95_w5gwgtnz5IQIzjjP2GnyexucHTq0MwdAH-AIQwODBmRbFPaARJ6uYAB062w3WB-MRlvTDSqMDlBrHdrYBtINdCqYn4CuHCgfUKViC4duYxKG4JEZHprt7i4326v1Cn0e-9gpPkVoHQfOUwP6qnrTxCI7oC04A_5l8qxVvYdXy32W7D5e76pP6c2X1bq6vEl1jnlItWgaQtu8IJRmuCY4B9xQzUgDXEFdkwLioWVLiCqbsmmB07olimSasRLTsySd2_p7OI61PDpzUO6XtMrIJfU9RiB5XhY8i_y7mT86-2MEH-TBeA19rwawo5cCc0FYxv4LZlEHKwSNIJ9B7az3Dtp_OxAsJ99yciknlzL6ljiXk-9Y92YZMNYHaB6rFsEReLsAymvVty6qMf6RKwpeFnjizmdub7r9vXEg9YNEBx6U03tJaNxDxu8V9A__5sMc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21044873</pqid></control><display><type>article</type><title>Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DESMEDT, Christine ; PIETTE, Fanny ; BERGH, Jonas ; LIDEREAU, Rosette ; ELLIS, Paul ; HARRIS, Adrian L ; KLIJN, Jan G. M ; FOEKENS, John A ; CARDOSO, Fatima ; PICCART, Martine J ; BUYSE, Marc ; SOTIRIOU, Christos ; LOI, Sherene ; YIXIN WANG ; LALLEMAND, Frangoise ; HAIBE-KAINS, Benjamin ; VIALE, Giuseppe ; DELORENZI, Mauro ; YI ZHANG ; SAGHATCHIAN D'ASSIGNIES, Mahasti</creator><creatorcontrib>DESMEDT, Christine ; PIETTE, Fanny ; BERGH, Jonas ; LIDEREAU, Rosette ; ELLIS, Paul ; HARRIS, Adrian L ; KLIJN, Jan G. M ; FOEKENS, John A ; CARDOSO, Fatima ; PICCART, Martine J ; BUYSE, Marc ; SOTIRIOU, Christos ; LOI, Sherene ; YIXIN WANG ; LALLEMAND, Frangoise ; HAIBE-KAINS, Benjamin ; VIALE, Giuseppe ; DELORENZI, Mauro ; YI ZHANG ; SAGHATCHIAN D'ASSIGNIES, Mahasti ; TRANSBIG Consortium ; on behalf of the TRANSBIG Consortium</creatorcontrib><description>Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results
and to compare the outcome with clinical risk assessment.
Experimental Design: Gene expression profiling of frozen samples from 198 N − systemically untreated patients was done at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic
risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were done with
the genomic risk and adjusted for the clinical risk, defined by Adjuvant! Online.
Results: The actual 5- and 10-year time to distant metastasis were 98% (88-100%) and 94% (83-98%), respectively, for the good profile
group and 76% (68-82%) and 73% (65-79%), respectively, for the poor profile group. The actual 5- and 10-year overall survival
were 98% (88-100%) and 87% (73-94%), respectively, for the good profile group and 84% (77-89%) and 72% (63-78%), respectively,
for the poor profile group. We observed a strong time dependence of this signature, leading to an adjusted hazard ratio of
13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for time to distant
metastasis and overall survival, respectively.
Conclusion: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene
expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-06-2765</identifier><identifier>PMID: 17545524</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>76-gene signature ; Adult ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor ; breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Female ; gene expression ; Gene Expression Profiling ; Genomics ; Gynecology. Andrology. Obstetrics ; Humans ; Lymphatic Metastasis ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Pharmacology. Drug treatments ; Prognosis ; Reproducibility of Results ; Risk ; Time Factors ; time-dependency ; Treatment Outcome ; Tumors</subject><ispartof>Clinical cancer research, 2007-06, Vol.13 (11), p.3207-3214</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c605t-c7dd13f6813320b106e0d3c41de5aebb18e8e839f11a9d9dfe53bf1a12c44903</citedby><cites>FETCH-LOGICAL-c605t-c7dd13f6813320b106e0d3c41de5aebb18e8e839f11a9d9dfe53bf1a12c44903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,309,310,314,776,780,785,786,881,3343,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18859804$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17545524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:115439292$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>DESMEDT, Christine</creatorcontrib><creatorcontrib>PIETTE, Fanny</creatorcontrib><creatorcontrib>BERGH, Jonas</creatorcontrib><creatorcontrib>LIDEREAU, Rosette</creatorcontrib><creatorcontrib>ELLIS, Paul</creatorcontrib><creatorcontrib>HARRIS, Adrian L</creatorcontrib><creatorcontrib>KLIJN, Jan G. M</creatorcontrib><creatorcontrib>FOEKENS, John A</creatorcontrib><creatorcontrib>CARDOSO, Fatima</creatorcontrib><creatorcontrib>PICCART, Martine J</creatorcontrib><creatorcontrib>BUYSE, Marc</creatorcontrib><creatorcontrib>SOTIRIOU, Christos</creatorcontrib><creatorcontrib>LOI, Sherene</creatorcontrib><creatorcontrib>YIXIN WANG</creatorcontrib><creatorcontrib>LALLEMAND, Frangoise</creatorcontrib><creatorcontrib>HAIBE-KAINS, Benjamin</creatorcontrib><creatorcontrib>VIALE, Giuseppe</creatorcontrib><creatorcontrib>DELORENZI, Mauro</creatorcontrib><creatorcontrib>YI ZHANG</creatorcontrib><creatorcontrib>SAGHATCHIAN D'ASSIGNIES, Mahasti</creatorcontrib><creatorcontrib>TRANSBIG Consortium</creatorcontrib><creatorcontrib>on behalf of the TRANSBIG Consortium</creatorcontrib><title>Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results
and to compare the outcome with clinical risk assessment.
Experimental Design: Gene expression profiling of frozen samples from 198 N − systemically untreated patients was done at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic
risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were done with
the genomic risk and adjusted for the clinical risk, defined by Adjuvant! Online.
Results: The actual 5- and 10-year time to distant metastasis were 98% (88-100%) and 94% (83-98%), respectively, for the good profile
group and 76% (68-82%) and 73% (65-79%), respectively, for the poor profile group. The actual 5- and 10-year overall survival
were 98% (88-100%) and 87% (73-94%), respectively, for the good profile group and 84% (77-89%) and 72% (63-78%), respectively,
for the poor profile group. We observed a strong time dependence of this signature, leading to an adjusted hazard ratio of
13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for time to distant
metastasis and overall survival, respectively.
Conclusion: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene
expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.</description><subject>76-gene signature</subject><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor</subject><subject>breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Female</subject><subject>gene expression</subject><subject>Gene Expression Profiling</subject><subject>Genomics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Reproducibility of Results</subject><subject>Risk</subject><subject>Time Factors</subject><subject>time-dependency</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAQgCMEoqXwCCBfQOohxY7tODm2oSwrlaXqrrhajjPJGrLxYjtUPAzvitMEekQ-eDT-5kf-kuQ1wReE8OI9waJIMaPZRVXdpThPM5HzJ8kp4VykNMv50xj_ZU6SF95_w5gwgtnz5IQIzjjP2GnyexucHTq0MwdAH-AIQwODBmRbFPaARJ6uYAB062w3WB-MRlvTDSqMDlBrHdrYBtINdCqYn4CuHCgfUKViC4duYxKG4JEZHprt7i4326v1Cn0e-9gpPkVoHQfOUwP6qnrTxCI7oC04A_5l8qxVvYdXy32W7D5e76pP6c2X1bq6vEl1jnlItWgaQtu8IJRmuCY4B9xQzUgDXEFdkwLioWVLiCqbsmmB07olimSasRLTsySd2_p7OI61PDpzUO6XtMrIJfU9RiB5XhY8i_y7mT86-2MEH-TBeA19rwawo5cCc0FYxv4LZlEHKwSNIJ9B7az3Dtp_OxAsJ99yciknlzL6ljiXk-9Y92YZMNYHaB6rFsEReLsAymvVty6qMf6RKwpeFnjizmdub7r9vXEg9YNEBx6U03tJaNxDxu8V9A__5sMc</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>DESMEDT, Christine</creator><creator>PIETTE, Fanny</creator><creator>BERGH, Jonas</creator><creator>LIDEREAU, Rosette</creator><creator>ELLIS, Paul</creator><creator>HARRIS, Adrian L</creator><creator>KLIJN, Jan G. M</creator><creator>FOEKENS, John A</creator><creator>CARDOSO, Fatima</creator><creator>PICCART, Martine J</creator><creator>BUYSE, Marc</creator><creator>SOTIRIOU, Christos</creator><creator>LOI, Sherene</creator><creator>YIXIN WANG</creator><creator>LALLEMAND, Frangoise</creator><creator>HAIBE-KAINS, Benjamin</creator><creator>VIALE, Giuseppe</creator><creator>DELORENZI, Mauro</creator><creator>YI ZHANG</creator><creator>SAGHATCHIAN D'ASSIGNIES, Mahasti</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>ADTPV</scope><scope>BNKNJ</scope></search><sort><creationdate>20070601</creationdate><title>Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series</title><author>DESMEDT, Christine ; PIETTE, Fanny ; BERGH, Jonas ; LIDEREAU, Rosette ; ELLIS, Paul ; HARRIS, Adrian L ; KLIJN, Jan G. M ; FOEKENS, John A ; CARDOSO, Fatima ; PICCART, Martine J ; BUYSE, Marc ; SOTIRIOU, Christos ; LOI, Sherene ; YIXIN WANG ; LALLEMAND, Frangoise ; HAIBE-KAINS, Benjamin ; VIALE, Giuseppe ; DELORENZI, Mauro ; YI ZHANG ; SAGHATCHIAN D'ASSIGNIES, Mahasti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c605t-c7dd13f6813320b106e0d3c41de5aebb18e8e839f11a9d9dfe53bf1a12c44903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>76-gene signature</topic><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor</topic><topic>breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Female</topic><topic>gene expression</topic><topic>Gene Expression Profiling</topic><topic>Genomics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Reproducibility of Results</topic><topic>Risk</topic><topic>Time Factors</topic><topic>time-dependency</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DESMEDT, Christine</creatorcontrib><creatorcontrib>PIETTE, Fanny</creatorcontrib><creatorcontrib>BERGH, Jonas</creatorcontrib><creatorcontrib>LIDEREAU, Rosette</creatorcontrib><creatorcontrib>ELLIS, Paul</creatorcontrib><creatorcontrib>HARRIS, Adrian L</creatorcontrib><creatorcontrib>KLIJN, Jan G. M</creatorcontrib><creatorcontrib>FOEKENS, John A</creatorcontrib><creatorcontrib>CARDOSO, Fatima</creatorcontrib><creatorcontrib>PICCART, Martine J</creatorcontrib><creatorcontrib>BUYSE, Marc</creatorcontrib><creatorcontrib>SOTIRIOU, Christos</creatorcontrib><creatorcontrib>LOI, Sherene</creatorcontrib><creatorcontrib>YIXIN WANG</creatorcontrib><creatorcontrib>LALLEMAND, Frangoise</creatorcontrib><creatorcontrib>HAIBE-KAINS, Benjamin</creatorcontrib><creatorcontrib>VIALE, Giuseppe</creatorcontrib><creatorcontrib>DELORENZI, Mauro</creatorcontrib><creatorcontrib>YI ZHANG</creatorcontrib><creatorcontrib>SAGHATCHIAN D'ASSIGNIES, Mahasti</creatorcontrib><creatorcontrib>TRANSBIG Consortium</creatorcontrib><creatorcontrib>on behalf of the TRANSBIG Consortium</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Conference</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DESMEDT, Christine</au><au>PIETTE, Fanny</au><au>BERGH, Jonas</au><au>LIDEREAU, Rosette</au><au>ELLIS, Paul</au><au>HARRIS, Adrian L</au><au>KLIJN, Jan G. M</au><au>FOEKENS, John A</au><au>CARDOSO, Fatima</au><au>PICCART, Martine J</au><au>BUYSE, Marc</au><au>SOTIRIOU, Christos</au><au>LOI, Sherene</au><au>YIXIN WANG</au><au>LALLEMAND, Frangoise</au><au>HAIBE-KAINS, Benjamin</au><au>VIALE, Giuseppe</au><au>DELORENZI, Mauro</au><au>YI ZHANG</au><au>SAGHATCHIAN D'ASSIGNIES, Mahasti</au><aucorp>TRANSBIG Consortium</aucorp><aucorp>on behalf of the TRANSBIG Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>13</volume><issue>11</issue><spage>3207</spage><epage>3214</epage><pages>3207-3214</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results
and to compare the outcome with clinical risk assessment.
Experimental Design: Gene expression profiling of frozen samples from 198 N − systemically untreated patients was done at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic
risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were done with
the genomic risk and adjusted for the clinical risk, defined by Adjuvant! Online.
Results: The actual 5- and 10-year time to distant metastasis were 98% (88-100%) and 94% (83-98%), respectively, for the good profile
group and 76% (68-82%) and 73% (65-79%), respectively, for the poor profile group. The actual 5- and 10-year overall survival
were 98% (88-100%) and 87% (73-94%), respectively, for the good profile group and 84% (77-89%) and 72% (63-78%), respectively,
for the poor profile group. We observed a strong time dependence of this signature, leading to an adjusted hazard ratio of
13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for time to distant
metastasis and overall survival, respectively.
Conclusion: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene
expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>17545524</pmid><doi>10.1158/1078-0432.CCR-06-2765</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2007-06, Vol.13 (11), p.3207-3214 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_569852 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | 76-gene signature Adult Antineoplastic agents Biological and medical sciences Biomarkers, Tumor breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - mortality Female gene expression Gene Expression Profiling Genomics Gynecology. Andrology. Obstetrics Humans Lymphatic Metastasis Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Prognosis Reproducibility of Results Risk Time Factors time-dependency Treatment Outcome Tumors |
| title | Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A36%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strong%20Time%20Dependence%20of%20the%2076-Gene%20Prognostic%20Signature%20for%20Node-Negative%20Breast%20Cancer%20Patients%20in%20the%20TRANSBIG%20Multicenter%20Independent%20Validation%20Series&rft.jtitle=Clinical%20cancer%20research&rft.au=DESMEDT,%20Christine&rft.aucorp=TRANSBIG%20Consortium&rft.date=2007-06-01&rft.volume=13&rft.issue=11&rft.spage=3207&rft.epage=3214&rft.pages=3207-3214&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-06-2765&rft_dat=%3Cproquest_swepu%3E21044873%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21044873&rft_id=info:pmid/17545524&rfr_iscdi=true |